ARWR News - Candlesense

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: European Society of...

Clinical trials

about 22 hours ago

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock ...

Will the cash and stock receipt have any impact on Arrowhead’s upcoming conference calls, guidance revisions, or analyst coverage? How will this milestone affect the valuation of Arrowhead’s pipeline assets, particularly the programs co‑developed with Sarepta? Does the receipt of this milestone trigger any covenants or changes in Arrowhead’s credit facilities or debt ratios?

Milestones

15 days ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is h...

Did the company address any changes in its commercial strategy or potential product launch timelines that could affect future revenue streams? What are the potential upside or downside risks associated with the upcoming regulatory milestones for the Phase 3 candidates? How does Arrowhead's Q3 performance and pipeline maturity compare to its direct competitors in the RNA‑targeted therapeutics space?

Earnings

21 days ago